A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Trabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue sarcoma. The drug has shown a high selectivity for myxoid liposarcoma, characterized by the translocation t(12;16)(q13; p11) leading to the expression of FUS-CHOP fusion gene. Trab...
| Հիմնական հեղինակներ: | , , , , , , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Public Library of Science (PLoS)
2012-01-01
|
| Շարք: | PLoS ONE |
| Առցանց հասանելիություն: | http://europepmc.org/articles/PMC3327679?pdf=render |